Xun Lin

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy

Alain Ravaud, Robert J. Motzer, Hardev Pandha et al. · New England Journal of Medicine · 2016 · 777 citations

Medicine, Oncology, Pharmacotherapy +17

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Neeraj Agarwal, Arun Azad, Joan Carles et al. · The Lancet · 2023 · 499 citations

Medicine, Pharmacology, Pharmacotherapy +12

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

Cora N. Sternberg, Karim Fizazi, Fred Saad et al. · New England Journal of Medicine · 2020 · 422 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

Sandrine Faivre, Éric Raymond, Éveline Boucher et al. · The Lancet Oncology · 2009 · 291 citations

Medicine, Oncology, Pharmacology +13

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results

Robert J. Motzer, Alain Ravaud, Jean‐Jacques Patard et al. · European Urology · 2017 · 223 citations · Full text

Medicine, Oncology, Pharmacology +10